NCRI 2018 | Targeting hypoxia in tumors with combination therapy
Kaye Williams, PhD, FSB, from the University of Manchester, Manchester, UK, provides an overview of the various therapeutic approaches targeting hypoxia in tumor cells, emphasizing current areas of interest. Prof. Williams highlights a potential role for immune checkpoint inhibitors, MEK inhibitors, AKT inhibitors, PI3K inhibitors and inhibitors of angiogenesis, in combination with radiotherapy to target hypoxia. Prof. Williams believes much is yet to be understood about the influence of various oncogenic signaling pathways on the tumor microenvironment, in order to develop combination therapies that will improve response rates. This video was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.
Get great new content delivered to your inboxSign up